Lexeo Therapeutics, Inc. Common Stock

LXEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
5.01 USD
↘ 0.12 (2.34%)AT CLOSE (11:59 AM EDT)
5.01
↘ 0.01 (0.10%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
5.01
↘ 0.01 (0.10%)
🔴Market: CLOSED

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $5.00 per share. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest LXEO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Aug 26, 2026.

Open?$5.10
High?$5.11
Low?$4.91
Prev. Close?$5.13
Volume?690.0K
Avg. Volume?968.6K
VWAP?$5.03
Rel. Volume?0.71x
Bid / Ask
Bid?$4.76 × 100
Ask?$5.22 × 3.0K
Spread?$0.46
Midpoint?$4.99
Valuation & Ratios
Market Cap?411.1M
Shares Out?82.0M
Float?73.2M
Float %?93.2%
P/E Ratio?N/A
P/B Ratio?1.75
EPS?-$1.06
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
59
Market Cap
420.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lexeotx.com
Listed
2023-11-03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: (212) 547-9879
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
20
Piotroski F-Score?0/9Weak
Altman Z-Score?9.81Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.98%Squeeze Risk
Short Interest?20.5M
Days to Cover?19.8
Free Float73.2M
Avg Daily Volume1.0M
Settlement Date2026-08-14
Financial Health
Current Ratio?13.89Strong
Quick Ratio?13.89Strong
Cash Ratio?5.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
81
1.75CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-37.1%WEAK▾
ROA?
S&P
3
-34.2%WEAK▾
Cash Flow & Enterprise
FCF?$-88698000
Enterprise Value?$318.8M
Fundamentals ratios updated end of day
MarketsMoversWatchlist